Nifelat R (Nifedipine)

Nifedipine blocks L‑type calcium channels in the smooth muscle of arteries. By preventing calcium entry, it causes the muscles to relax, leading to vasodilation, reduced peripheral resistance, lower blood pressure, and decreased cardiac workload.

The specific dose of Nifelat R is determined by the prescribing clinician based on the patient’s condition, response, and other medical factors. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Safety data for nifedipine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nifelat R (nifedipine) is a dihydropyridine calcium channel blocker, distinct from beta‑blockers, ACE inhibitors, or diuretics. It is particularly effective for patients who need rapid vasodilation, but may cause peripheral edema more often than some other classes.

Nifelat R should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture and direct sunlight to maintain product stability.

Nifelat R is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s guidance on timing and any dietary considerations.

Serious risks include severe hypotension, myocardial infarction, and rare cases of hepatic dysfunction. Patients should be monitored for signs of these conditions, especially during dose initiation or when combined with interacting medications.

Nifelat R is contraindicated in patients with known hypersensitivity to nifedipine or any component of the formulation, and in those with severe aortic stenosis or uncontrolled heart failure. Clinicians should assess each patient’s medical history before prescribing.